GH Research to Present at RBC Capital Markets Psychedelics Symposium

GH Research ( (GHRS) ) has issued an update.

On January 22, 2026, GH Research PLC announced it will participate in a virtual panel discussion at the RBC Capital Markets Psychedelics Symposium: A Trip Into The Future of Mental Health, highlighting its engagement with investors and industry stakeholders in the emerging psychedelic therapeutics space. The participation underscores the company’s efforts to raise its profile within capital markets and the broader mental health innovation community, potentially supporting visibility for its pipeline and strategy as the psychedelic medicine field continues to attract institutional attention.

The most recent analyst rating on (GHRS) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.

Spark’s Take on GHRS Stock

According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.

The score is held back primarily by weak operating fundamentals (no revenue, widening losses, and significant cash burn), partially offset by a strong, low-debt balance sheet. Technicals are moderately supportive with price above key moving averages, while valuation remains constrained due to negative earnings and no dividend data.

To see Spark’s full report on GHRS stock, click here.

More about GH Research

GH Research PLC is a foreign private issuer listed in the United States and headquartered in Dublin, Ireland, operating in the biopharmaceutical sector with a focus on innovative mental health treatments, including psychedelic-based therapies. The company targets the evolving market for novel psychiatric interventions, positioning itself within the growing psychedelic medicine ecosystem.

Average Trading Volume: 451,409

Technical Sentiment Signal: Buy

Current Market Cap: $977M

See more insights into GHRS stock on TipRanks’ Stock Analysis page.